UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 8-K

  

 

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): August 11, 2015

  

 

 

Oramed Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-35813   98-0376008
(Commission File Number)   (IRS Employer Identification No.)

 

Hi-Tech Park 2/4 Givat Ram, PO Box 39098,
Jerusalem, Israel
  91390
(Address of Principal Executive Offices)   (Zip Code)

 

+972-2-566-0001

(Registrant’s Telephone Number, Including Area Code) 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

Item 5.07.  Submission of Matters to a Vote of Security Holders.

 

The Company held its annual meeting of stockholders on August 11, 2015. The final voting results are set forth below.

Stockholders voted on the following proposals:

Proposal No. 1 — Re-election of Directors.

The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows:

Director Name

 

For

  

Against

  

Abstain

  

Broker Non-Votes

 
Nadav Kidron   3,469,253    101,687    14,717    3,322,933 
                     
Miriam Kidron   3,466,710    102,596    16,351    3,322,933 
                     
Leonard Sank   3,492,857    51,665    41,135    3,322,933 
                     
Harold Jacob   3,504,880    39,942    40,835    3,322,933 
                     
Michael Berelowitz   3,467,144    100,805    17,708    3,322,933 
                     
Gerald Ostrov   3,505,725    39,497    40,435    3,322,933 

 

Proposal No. 2 — Ratification of Auditors.

The stockholders ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the fiscal year ending August 31, 2015. The votes were as follows:

For

  

Against

  

Abstain

  

Broker Non-Votes

 
                  
 6,699,311    59,389    149,890    N/A 

2
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

 

  Oramed Pharmaceuticals Inc.
     
Date: August 12, 2015 By: /s/ Nadav Kidron
  Name: Nadav Kidron
  Title: President and CEO

 

 

3